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T2DM typically progresses from a state of prediabetes (that is, insulin resistance coupled with hyperinsulinemia that is able to maintain euglycemia) to an overt state of diabetes that is caused by beta cell failure and impaired insulin secretion and thus marked by fasting hyperglycemia 1 . The pathogenic role of inflammation in both stages of T2DM is increasingly recognized. Adipose tissue inflammation contributes to insulin resistance through proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) (ref. 2) , and infiltration of proinflammatory cells into pancreatic islets of subjects and animals with diabetes may contribute to beta cell failure 3 . Furthermore, the Nlrp3 inflammasome, a protein complex involved in the proteolytic activation of caspase-1 and interleukin-1β (IL-1β) secretion, has been implicated in the pathogenesis of diabetogenic insulitis [4] [5] [6] [7] .
Endocannabinoids, or lipid ligands of G protein-coupled CB 1 R and CB 2 R, produce a broad range of biological effects 8 . CB 1 R activation promotes food intake 9 , increases lipogenesis in adipose tissue 10 and liver 11, 12 and induces insulin resistance and dyslipidemia 13, 14 . These effects suggest that an overactive endocannabinoid-CB 1 R system contributes to the development of visceral obesity and its complications 15 . Accordingly, chronic CB 1 R blockade reduces body weight and improves obesity-related insulin resistance, dyslipidemia and fatty liver both in obese rodents 16, 17 and in humans 18, 19 . CB 1 R blockade also improves glycemic control as a monotherapy in drug-naive subjects with T2DM 20 . However, the therapeutic development of CB 1 R antagonists or inverse agonists has been halted due to adverse psychiatric effects, which are likely caused by central activation of these receptors as opposed to their peripheral effects 21 .
In mice with high-fat diet-induced obesity (DIO), selective blockade of peripheral CB 1 R replicates the metabolic benefit of global CB 1 R blockade without adverse behavioral effects 22, 23 . DIO mice are insulin resistant, but their fasting blood glucose is only moderately higher compared to wild-type mice owing to compensatory hyperinsulinemia. Leptin-resistant Zucker fatty (fa/fa) rats are also obese (due to a recessive mutation in the gene encoding the leptin receptor) and are similarly insulin resistant but remain normoglycemic as a result of compensatory beta cell growth 24 . In contrast, the ZDF rat, derived from the Zucker fatty rat by inbreeding for fasting hyperglycemia, replicates the natural history of human T2DM 25 . Young ZDF rats (up to 7 weeks old) are insulin resistant with hyperinsulinemia and normoglycemia but become extremely hyperglycemic with decreasing hyperinsulinemia by 9 weeks of age, which reflects rapidly progressing beta cell failure. Treatment of ZDF rats with brain-penetrant CB 1 R antagonists was recently reported to reduce their hyperglycemia and increase both plasma and islet insulin levels, suggesting beta cell protection, although the underlying mechanisms, including the tissue localization of the CB 1 Rs involved and their downstream targets, remain unclear 26 . One possible target is CB 1 Rs on beta cells, the activation of which can facilitate proapoptotic signaling through an autocrine mechanism 27 similar to an inflammasome-mediated autocrine signaling implicated in lipotoxic beta cell death 28, 29 . Alternatively, activation of macrophage CB 1 Rs can induce transmigration and proinflammatory signaling 30 , which could kill beta cells through a paracrine mechanism. Finally, as central mechanisms may regulate beta cell function 31 and survival 32 , and endocannabinoids can also influence glycemic control through activation of CB 1 Rs in the CNS 33 , they may induce beta cell death through neural input from the brain.
Here we demonstrate, using a combination of pharmacological and genetic tools, that beta cell loss in ZDF rats is induced through a paracrine mechanism by inflammatory cytokines, including IL-1β, released from infiltrating M1 macrophages as a result of CB 1 Rmediated selective activation of the Nlrp3-ASC inflammasome in the macrophages. These effects can be prevented by peripheral CB 1 R blockade or selective knockdown of macrophage CB 1 R.
RESULTS

Peripheral CB 1 R blockade delays the progression of T2DM
We treated 8-week-old male diabetic ZDF rats orally with the non-brainpenetrant CB 1 R inverse agonist JD5037 (ref. 23) or vehicle for 28 d. Relative to lean littermates, vehicle-treated ZDF rats were obese and hyperphagic (Fig. 1a) , had higher hepatic concentration of triglycerides and higher expression of the lipogenic genes Fas and Scd1 (Fig. 1b) and had overt diabetes, indicated by pronounced hyperglycemia, higher hemoglobin A1c (HbA1c) levels and moderate hyperinsulinemia (Fig. 1c) . Furthermore, they had extremely high plasma triglyceride and cholesterol concentrations (Supplementary Table 1) .
Chronic JD5037 treatment of ZDF rats did not affect body weight or adiposity and was associated with a slightly lower amount of food intake than in vehicle-treated ZDF rats (Fig. 1a) , whereas the steatosis, the associated hepatocellular damage and the lipogenic gene expression were significantly lower (Fig. 1b) . JD5037-treated ZDF rats were euglycemic, whereas their plasma insulin and C-peptide levels were paradoxically higher compared to vehicle-treated ZDF rats (Fig. 1c) , suggesting improved beta cell function and survival. The inactive diastereomer of JD5037 (ref. 23 ) did not affect plasma glucose, insulin or C-peptide levels (Supplementary Fig. 1 ). Normoglycemia coupled with hyperinsulinemia in JD5037-treated rats suggests continued insulin resistance. Indeed, the insulin resistance of ZDF rats, which was primarily due to decreased peripheral glucose uptake, was not significantly affected by JD5037, as revealed by euglycemichyperinsulinemic clamps (Fig. 1d) .
JD5037 treatment also normalized insulin mRNA and protein levels in ZDF islets, probably by preventing beta cell apoptosis. This is indicated by the lower number of TUNEL-positive islet cells (Fig. 2a) , the lower expression of the apoptotic markers Bak1, Bax, Fas, Faslg and Tnfrsf1a and the higher expression of the antiapoptotic markers Bcl2 and Bcl2l1 as compared to vehicle-treated ZDF rats (Supplementary Fig. 2a ). At the same time, JD5037 treatment was associated with greater beta cell mass compared to that in vehicletreated rats (Supplementary Fig. 2b ), probably as a result of higher gene expression of transcription factors involved in beta cell survival, such as Pdx1, Mafa and Neurog3 (Supplementary Fig 2c) , and also reflected by more insulin-producing beta cells expressing the proliferation marker Ki67 (Supplementary Fig. 2d ). The higher expression of Cnr1 and amounts of anandamide in islets of ZDF compared to lean littermates was not observed in JD5037-treated ZDF rats (Fig. 2a) .
The loss of insulin-producing beta cells in ZDF rats was paralleled by the absence of glucose-stimulated insulin secretion (GSIS), as assessed in vivo by measuring plasma insulin and C-peptide within 5 min of a glucose load and in vitro in isolated perfused islets. The basal hyperinsulinemia of JD5037-treated rats was similar to that in a c *** Glucose (mg dl vehicle-treated ZDF rats, but it correlated with a normal GSIS response both in vivo and in vitro (Fig. 2b) . In parallel, JD5037 treatment was associated with normal expression in pancreatic islets of glucokinase (Gck) and of Glut2 (Slc2a2) (Fig. 2c) , which mediates glucose uptake by beta cells. After we treated 6-week-old prediabetic ZDF rats with JD5037 daily for 3 months, their hyperglycemia was lower and its development much slower than in vehicle-treated age-matched ZDF rats, and the rapid decline in plasma insulin and C-peptide was largely prevented (Fig. 2d) . Thus, peripheral CB 1 R blockade delays the progression of T2DM and the loss of beta cell function. CB 1 R blockade reverses macrophage infiltration in ZDF islets ZDF islets were enlarged with robust infiltration by CD68 + macrophages (Fig. 3a) of the M1 phenotype, as indicated by higher Tnf and Nos2 and lower Tgfb1, Il10 and Arg1 expression in islets from ZDF compared to lean littermates (Fig. 3b) . JD5037 treatment reduced macrophage infiltration and caused an M1-to-M2 shift (Fig. 3a,b) . Islets from ZDF relative to lean littermates contained more Nlrp3, IL-1β (Il1b) and IL-18 (Il18) at both the mRNA and the protein levels, had more p65-NFκB protein and higher caspase-1 activity (Fig. 3c) and had similarly higher gene expression of the thioredoxin-interacting protein (Txnip) 34 and the IL-1 receptor (Il1r1) (Fig. 3c) . In contrast, the same parameters in JD5037-treated ZDF rats were similar to or only slightly different from their levels in lean littermates, whereas expression of the IL-1R antagonist (Il1rn) was significantly higher (Fig. 3c) .
The assembly of the functional inflammasome involves the interaction of the pyrin domains of Nlrp3 and the adaptor protein ASC 35 . Levels of the mRNA encoding ASC (Pycard) were higher in islets of ZDF rats compared to lean littermates and were normalized by JD5037 treatment. The expression of other inflammasomes, such as Nlrp6, Nlrp12 and Mnda, was similar in lean and ZDF rats, and the slightly higher expression of Aim2 in ZDF rats was unaffected by JD5037 treatment (Supplementary Fig. 3a) . In islets from lean rats, both anandamide (1 µM) and the positive control lipopolysaccharide (LPS) (10 ng ml −1 ) increased ASC protein levels and the active, cleaved forms (p45 and p10) of caspase-1 (Supplementary Fig. 3b) .
The anti-inflammatory function of adiponectin is well recognized 36 , and its effects are mediated by Adipor1 and Adipor2, both of which are abundantly expressed in islet beta cells 37 . Plasma concentrations of adiponectin (Supplementary Table 1 ) and levels of Adipor1 and Adipor2 mRNA in islets were lower in ZDF than in lean rats, whereas in JD5037-treated ZDF rats they were similar to those in lean controls (Supplementary Fig. 3c ). Uric acid has been implicated in proinflammatory changes, decreased adiponectin production 38 and activation of the Nlrp3 inflammasome 39 . Plasma concentrations of uric acid were higher in ZDF rats than in lean rats, whereas JD5037-treated ZDF rats had similar concentrations to those in lean littermates (Supplementary Table 1) .
Both CB 1 R and Nlrp3 were highly coexpressed with CD68 in pancreatic islets (72.3 ± 5.9% and 84.9 ± 9.8% colocalization, respectively), whereas tissue distribution of CB 1 R and insulin did not overlap (5.4 ± 3.7% colocalization) ( Supplementary Fig. 4 ).
Macrophage depletion delays the onset of T2DM
In ZDF rats treated with liposomes containing clodronate, a chemical agent inducing macrophage apoptosis 40 , the onset of hyperglycemia and the progressive decline in plasma insulin and C-peptide were In the left and middle graphs, the yellow segment indicates the glucose-induced increase in plasma insulin or C-peptide, respectively, over baseline insulin levels shown in white, gray or black; n = 10 rats or 8 islet preparations per group; *P < 0.05, **P < 0.01, ***P < 0.001 relative to baseline plasma insulin level or value in corresponding group of islets on 0.5 g l −1 glucose. (c) Slc2a2 and Gck expression in islets from lean, vehicle-treated or JD5037-treated ZDF rats; n = 10 preparations per group; P values as in a. (d) Baseline blood glucose, insulin and C-peptide levels in 6-week-old prediabetic ZDF rats and their biweekly change during 12 weeks of daily treatment with vehicle (gray columns and squares) or JD5037 (black columns and triangles). Mean ± s.e.m. values in age-matched lean controls are shown by white columns and open circles; n = 10 rats per group during weeks 6-18. Significant difference from corresponding value in lean (*P < 0.05, **P < 0.005 or ***P < 0.001) or vehicle-treated ( ### P < 0.001) ZDF rats. Scale bars, 50 µm.
npg slower than in ZDF rats treated with empty liposomes, whereas both groups remained insulin resistant (Fig. 4a) , similar to the insulin resistance of both vehicle-treated and JD5037-treated rats. Macrophage infiltration of islets and expression of the macrophagederived cytokines monocyte chemoattractant protein-1 (MCP-1) and TNF-α were lower in clodronate-treated than in empty liposome-treated ZDF rats (Fig. 4b) . Pancreatic anandamide content, Cnr1, Nlrp3 and Txnip expression and Nlrp3 protein expression were similarly lower in clodronate-treated than in empty liposome-treated rats, which is compatible with infiltrating macrophages being their main source. Pancreatic insulin content was moderately higher in the former compared to the latter group (Fig. 4b) .
Selective knockdown of macrophage CB 1 R alleviates T2DM We injected ZDF rats intraperitoneally (i.p.) daily with CB 1 R siRNA delivery vehicles composed of β1,3-d-glucan-encapsulated siRNA particles (GeRPs) for 10 d to induce macrophage-specific knockdown of CB 1 R (refs. 41, 42) . Controls received GeRPs containing scrambled siRNA. The siRNA selected for in vivo use produced dose-dependent, >95% suppression of CB 1 R mRNA and no change in CB 2 R mRNA in thioglycollate-induced peritoneal elicited macrophages (PECs) (Supplementary Fig. 5a ). We analyzed the selective uptake of GeRPs in peripheral blood leukocytes or PECs collected at the end of treatment and immunostained for CD68 and CD3 for FACS analysis. As previously reported 41 , GeRPs were undetectable in peripheral blood monocytes ( Supplementary  Fig. 5b ), whereas GeRPs were enriched approximately tenfold in CD68 + PECs compared to CD3 + lymphocytes ( Supplementary  Fig. 5c ). Furthermore, in purified populations of peritoneal cells prepared by FACS, Cnr1 was suppressed by 80% in CD68 + FITC + PECs (in which the glucan shell is labeled with FITC) from ZDF rats treated with CB 1 R GeRPs compared to those treated with scrambled GeRPs, with no change in Cnr2 expression (Supplementary Fig. 5d ). Neither Cnr1 nor Cnr2 expression was affected by CB 1 R GeRP treatment in CD3 + lymphocytes (Supplementary Fig. 5e ).
ZDF rats treated with CB 1 R siRNA remained normoglycemic and hyperinsulinemic, whereas those receiving scrambled siRNA developed progressive hyperglycemia and a decline in plasma insulin and C-peptide similarly to vehicle-treated ZDF rats (Fig. 5a) . CB 1 R siRNA treatment also resulted in higher insulin expression and content in islets and lower macrophage infiltration and islet expression of Nlrp3, Pycard, Il1b, Il18, Cnr1 and Ccl2 than did scrambled siRNA treatment (Fig. 5b) . These effects were similar to those caused by JD5037 or clodronate treatment.
Glucose and palmitate boost macrophage anandamide levels Islets isolated from ZDF rats had higher concentrations of anandamide, associated with lower activity of the enzyme that degrades it, fatty acid amide hydrolase (FAAH), and higher expression of its biosynthetic enzyme, N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD), as compared to islets from lean rats or ZDF rats chronically treated with JD5037 (Supplementary Fig. 6a) .
In contrast, concentrations of 2-arachidonoylglycerol (2-AG), the activity of the enzyme that degrades it, monoacylglyceride lipase, and the expression of its biosynthetic enzyme, diacylglycerol lipase-β (Daglb), were similar in the three groups, whereas Dagla expression was lower in islets from ZDF rats than in islets from lean littermates (Supplementary Fig. 6a ). NAPE-PLD was not coexpressed with insulin in islets (Supplementary Fig. 6b ). Incubation of PECs from lean rats with 250 µM palmitate or 33 mM glucose caused a modest or marked increase in anandamide levels, respectively, with the combination of the two having an additive effect (Supplementary Fig. 6c ).
Proinflammatory effect of anandamide is through macrophages
To further define the cells responsible for CB 1 R-mediated proinflammatory signaling, we tested anandamide in RAW264.7 macrophages and MIN6 insulinoma cells, as well as in primary cultured human macrophages and PECs from wild-type, Cnr1 −/− and Nlrp3 −/− mice. In RAW264.7 cells, anandamide markedly increased the secretion of IL-1β, TNF-α and MCP-1, with peak changes observed at 0.5 µM, whereas it did not affect the much lower levels of these cytokines detectable in the medium of MIN6 cells relative to vehicle treatment (Supplementary Fig. 7a) . Similarly, the expression of Nlrp3, Casp1 and Cnr1 was much higher in macrophages exposed to anandamide compared to macrophages exposed to vehicle, whereas Cnr2 expression was similar between the two groups. No differences in the expression of any of these genes were observed in MIN6 cells incubated with anandamide compared to vehicle (Supplementary Fig. 7a) .
The above findings suggest that endocannabinoids induce beta cell apoptosis indirectly through macrophage-derived cytokines, but they could also act directly on CB 1 Rs present on beta cells 43 . We therefore compared the effects of maximally effective concentrations of anandamide and IL-1β on the gene expression of pro-and antiapoptotic proteins and insulin in MIN6 cells (Supplementary Fig. 7b ).
Anandamide (10 µM) had little or no effect on pro-and antiapoptotic gene expression, whereas IL-1β (30 ng ml −1 ) markedly induced the expression of the proapoptotic genes Bak1 and Bax and drastically suppressed the expression of the antiapoptotic genes Bcl2 and Bcl2l1. IL-1β was similarly more potent than anandamide in influencing pro-and antiapoptotic gene expression in isolated human islets, indicating that effects seen in MIN6 cells are not unique to that tumor cell line ( Supplementary  Fig. 7c ). IL-1β also drastically reduced the expression of Cnr1 and CB 1 R protein in MIN6 cells, and this effect was blocked by the IL-1R antagonist (Supplementary Fig. 7d) .
We then analyzed the mechanism of the proinflammatory effect of anandamide in mouse PECs. Anandamide, relative to vehicle, induced proinflammatory gene expression in PECs from wild-type but not Cnr1 −/− or Nlrp3 −/− mice, whereas the expression of these genes was similarly higher in the presence of the LPS positive control compared to vehicle in cells from wild-type and Cnr1 −/− but not Nlrp3 −/− mice ( Supplementary Fig. 8a,b) . This indicates the exclusive role of CB 1 R and its downstream target Nlrp3 in mediating these effects. In agreement with earlier findings 14 , acute in vivo treatment with anandamide (10 mg per kg body weight i.p.) induced whole-body insulin resistance in wild-type mice but failed to affect insulin-induced hypoglycemia in Nlrp3 −/− mice, which, as reported by others 44 , were supersensitive to insulin (Supplementary Fig. 8c ).
There was also CB 1 R-mediated inflammasome activation in human macrophages isolated from peripheral blood of 29 healthy subjects: in vitro incubation of such cells with anandamide resulted in higher NLRP3, PYCARD, IL1B, IL18 and CNR1 expression, lower CNR2 expression and higher IL-1β and IL-18 secretion relative to that in vehicle-treated aliquots of the same cells, and no such differences were detectable in the added presence of 100 nM JD5037 (Fig. 6a) .
We also assessed the effects of anandamide, IL-1β and high glucose in islets isolated from lean and ZDF rats (Fig. 6b) . IL-1β secretion npg in aliquots of ten islets per replicate was higher in the presence than in the absence of either high glucose (33 mM) or anandamide (1 µM), with glucose being more effective than anandamide, and these differences were significantly greater in islets from ZDF compared to lean rats. IL-1β (30 ng ml −1 ), in turn, caused greater release of the chemokine MCP-1 and of IL-6 relative to vehicle, and this difference was amplified in ZDF islets, whereas high glucose had no such effect, and anandamide caused greater release than did vehicle of MCP-1 and IL-6 only in ZDF islets (Fig. 6b) . None of these stimuli influenced TNF-α release. Finally, we replicated the greater effect of high glucose than anandamide on IL-1β release and IL-1β-induced MCP-1 release in normal human islets (Fig. 6c) .
DISCUSSION
There is growing recognition that islet inflammation is involved in the progression of compensated insulin resistance to insulin-dependent T2DM, but the primary proinflammatory signal and its cellular target within the pancreatic islet have remained unidentified. Here we demonstrate that endocannabinoids acting through peripheral CB 1 Rs mediate the progression of diabetes and the associated beta cell loss in a rat model of insulin-dependent T2DM. We further show that the CB 1 Rs mediating these effects are located on infiltrating macrophages, where their activation induces the Nlrp3-ASC inflammasome and the proteolytic activation and release of IL-1β and IL-18, which act as paracrine signals to induce beta cell apoptosis. The NOD-like receptors (NLRs) serve as intracellular platforms for the assembly of protein complexes or inflammasomes that coordinate inflammatory responses. Among the family of NLRs, the Nlrp3 inflammasome is unique in its ability to recognize molecular patterns associated with host-derived danger signals, such as certain metabolites, and thus sense metabolic stress. Indeed, increased expression and activity of the Nlrp3 inflammasome in the pancreas has been associated with beta cell death in a rodent model of DIO and T2DM 5, 34 . Here we show that peripheral CB 1 R blockade, compared with vehicle treatment, is associated with lower expression of Nlrp3 and the associated proteins Txnip and ASC in the islets of ZDF rats and delayed onset of markedly blunted hyperglycemia. This indicates that activation of CB 1 Rs is the primary signal responsible for inflammasome activation and the resulting metabolic consequences. Metabolic factors known to activate Nlrp3 include K + efflux 45 , reactive oxygen species 45 and a lowering of cAMP levels 46 , and all three can be triggered by activation of G i /G o -coupled CB 1 R (refs. 8, 30) . Another possible link is c-Jun N-terminal kinase (JNK), which is activated by CB 1 R (ref. 47) , and macrophage JNK is implicated in obesity-induced insulin resistance and inflammation 48 . Any or all of these mechanisms could contribute to the CB 1 R-mediated increase in Nlrp3 expression.
Pancreatic beta cells express both endocannabinoids and CB 1 R (refs. 43, 49) , and activation of CB 1 R under in vitro conditions promotes apoptosis by inhibiting insulin signaling 27, 43 . Additionally, the thioredoxin-interacting protein TXNIP, a signaling molecule that links endoplasmic reticulum stress to activation of the Nlrp3 inflammasome, has been linked to lipotoxic beta cell death through an autocrine mechanism documented under in vitro conditions 28, 29 . Together, these findings could suggest that endocannabinoids induce beta cell death by acting directly on beta cells. Instead, we present four lines of evidence in support of an alternative, paracrine mechanism of beta cell death operating in vivo through activation of CB 1 Rs on infiltrating macrophages to induce the production and release of proinflammatory cytokines, which then cause the apoptosis of neighboring beta cells.
First, CB 1 R and Nlrp3 in the islets of diabetic ZDF rats colocalize with CD68 + macrophages, but not with insulin-producing beta cells. Macrophages are known to express not only CB 1 R 30 , but also endocannabinoids 50 , with both being upregulated under proinflammatory conditions 30, 51 , and stimulation of macrophage CB 1 R increases the Figure 5 Effects of macrophage-selective siRNA knockdown of CB 1 R in ZDF rats. (a) Baseline blood glucose in 8-week-old ZDF rats during 10 d of treatment with scrambled (Scrb) GeRPs (gray columns and circles) or CB 1 R GeRPs (black columns and squares) and plasma insulin, C-peptide and pancreatic AEA levels at end of treatment. n = 6-8 rats per group; *P < 0.05, **P < 0.01, ***P < 0.001. (b) Top, immunohistochemistry stains for islet insulin, macrophages and CB 1 R and Nlrp3 protein (with arrows marking antigen-positive cells). Scale bars, 50 µm. Bottom, mRNA expression of Ins1, Cd68, Cnr1, Nlrp3, Il18, Il1b, Tnf, Ccl2 and Pycard in islets isolated from ZDF rats treated with scrambled (gray) or CB 1 R GeRPs (black); n = 6 per group. *P < 0.05, **P < 0.01, ***P < .001. Data are expressed as means ± s.e.m. npg production of the chemokine MCP-1 (ref. 30) , which would promote transmigration of macrophages into islets. Accordingly, the expression of Ccl2 was higher in the pancreas of ZDF rats compared to lean controls and lower after JD5037 treatment.
Second, clodronate-induced depletion of macrophages or peripheral CB 1 R blockade were associated with similarly slower and less severe progression of T2DM and the associated macrophage infiltration and Nlrp3 activation in pancreatic islets. The pancreatic expression of Txnip was also lower in clodronate-treated rats than in controls, indicating that it is triggered by infiltrating proinflammatory cells. This is further supported by the ability of IL-1β, but not anandamide, to increase Txnip expression in beta cells in vitro and by the recent observation that endoplasmic reticulum stress causes a much more robust release of active IL-β in macrophages than in beta cells 29 . Furthermore, the findings that CB 1 R agonists do not activate caspase or impair insulin release in cultured beta cells, whereas cytokines elicit their apoptosis 52 , further support the dominance of a paracrine rather than autocrine mechanism of beta cell death.
Third, the endocannabinoid anandamide induced the Nlrp3 inflammasome and the inflammatory cascade it orchestrates in vitro in rodent and human macrophages, but not in MIN6 insulinoma cells, and IL-1β robustly induced proapoptotic and suppressed anti-apoptotic gene expression in MIN6 cells. These effects may be facilitated by the observed upregulation of IL-1 receptors in the pancreas in T2DM. At the same time, the gene expression of the IL-1 receptor antagonist, a protein with therapeutic efficacy in T2DM 53 , was higher in islets from JD5037-treated compared to vehicle-treated rats. The IL-1β-induced robust downregulation of Cnr1 in MIN6 cells would further attenuate a direct effect of anandamide on neighboring beta cells. The anandamide-induced 'autoinduction' of CB 1 R expression in macrophages, also noted in other tissues 54 , may represent a feedforward mechanism whereby the initial CB 1 R-mediated inflammatory signaling is amplified through upregulation of the receptor. Additionally, the exclusive role of CB 1 R and Nlrp3 in mediating the proinflammatory effects of anandamide is indicated by the absence of these effects in macrophages from Cnr1 −/− or Nlrp3 −/− mice.
Fourth and most notably, selective in vivo knockdown of macrophage CB 1 R fully replicates the effect of pharmacological CB 1 R blockade in restoring normoglycemia by protecting and restoring beta cell functions. Selective knockdown of macrophage CB 1 R also prevented macrophage infiltration of the islets and the increases in pancreatic anandamide, CB 1 R, MCP-1, Nlrp3 and Il-1β, as compared to scrambled siRNA-treated controls. This indicates that activation of macrophage CB 1 Rs by endogenous anandamide is not only the signal for inflammasome activation but also a trigger for the production of the chemokine that promotes the transmigration of macrophages into the pancreas. 
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Of the two main endocannabinoids, anandamide levels are higher in the islets of ZDF compared to those of lean rats as a result of both its increased biosynthesis and decreased degradation by FAAH in the former, whereas 2-AG levels remain similar in the two groups. High glucose and palmitate levels may be the triggers for the diabetesrelated increase in anandamide in proinflammatory macrophages. The diabetogenic role of anandamide is supported by the finding that chronic anandamide treatment of lean mice induces glucose intolerance and muscle macrophage infiltration 55 . Further, the selective increase in plasma anandamide, but not 2-AG, correlates with increased body mass and proinflammatory metabolite levels in subjects with diabetes 56 , though others have reported higher concentrations of both endocannabinoids in subjects with diabetes compared to healthy subjects 15 .
Beta cell survival may be improved indirectly through reversal of insulin resistance. However, this is not the mechanism of the improved beta cell function in JD5037-treated ZDF rats, which remained insulin resistant. This unexpected finding is probably related to the paradoxical increase in the hyperinsulinemia resulting from the improved beta cell survival in JD5037-treated ZDF rats, as hyperinsulinemia can drive, rather than simply compensate for, insulin resistance 57 . Conditions are different in insulin-resistant DIO mice, in which beta cell function is not compromised and CB 1 R blockade has been found to reverse both hyperinsulinemia and insulin resistance 22, 23 . The CB 1 R-mediated insulin resistance in these models may also involve inflammasome activation, as suggested by our finding that anandamide induced insulin resistance in wild-type but not Nlrp3 −/− mice.
Beta cell apoptosis may also be secondary to hypothalamic inflammation 32 . However, such a central mechanism is an unlikely target of JD5037 because the low brain penetrance of the compound does not lead to significant brain CB 1 R occupancy 23 . Also, selective downregulation of peripheral CB 1 R levels by CB 1 R antisense oligonucleotides is associated with improved metabolic profile in AKR mice with DIO 58 . Although we cannot absolutely rule out off-target effects of JD5037, a possible non-CB 1 R target for JD5037 or one of its metabolites is unlikely in view of the lack of antidiabetic effects of its CB 1 R-inactive diastereomer.
The dominant role of macrophages in progressive beta cell death, as indicated here, does not exclude the possible role of beta cells in initiating diabetic insulitis through glucose-induced IL-1β release 59 , which stimulates secretion of the chemokine MCP-1. MCP-1 promotes macrophage infiltration, which then drives progressive islet inflammation and beta cell death. The pathogenic role of infiltrating macrophages may also apply to human T2DM: macrophages isolated from individuals with diabetes express more Nlrp3 and secrete more IL-1β than macrophages from healthy controls 7 , and these changes are probably triggered by endocannabinoid activation of CB 1 R, as indicated by the present findings. Macrophages also express CB 2 R, whose stimulation suppresses proinflammatory cytokine production 60 . It remains to be seen whether selective CB 2 R agonists may also be effective in protecting beta cells in T2DM.
In summary, we provide multiple lines of evidence for the key role of macrophage-derived anandamide in beta cell loss in T2DM, as illustrated schematically in Figure 6d , and identify CB 1 R on macrophages as a new therapeutic target.
METHODS
Methods and any associated references are available in the online version of the paper. Preparation and in vivo administration of glucan-encapsulated siRNA particles. FITC-labeled glucan shells were prepared as previously described 68 . To prepare a glucan-encapsulated siRNA particle (GeRP) dose for one rat, 30 nmol siRNA (Dharmacon) were incubated with 500 nmol Endo-Porter (Gene Tools) in 30 mM sodium acetate (pH 4.8) for 15 min at room temperature in a final volume of 200 µl. The siRNA-Endo-Porter solution was added to 10 mg (~10 10 particles) of FITC-glucan shells and then vortexed and incubated for 1 h. The siRNA-loaded GeRPs were then resuspended in 5 ml PBS and sonicated to ensure homogeneity of the GeRP preparation.
Twelve 8-week old ZDF rats were then injected i.p. once daily for 10 d with 5.6 mg per kg body weight GeRPs loaded with 2.1 mg per kg body weight EP and 0.262 mg per kg body weight siRNA. Six rats were then treated with a scrambled siRNA (sense CAGUCGCGUUUGCGACUGGUU, antisense CCAGUCG-CAAACGCGACUGUU), and six other rats received an siRNA directed against Cnr1 (sense GCAUCAAGAGCACCGUUAAUU, antisense UAACGGUGCUCUUGAUG-CUU).
Cell preparation and FACS analysis of CD3 + and CD68 + cells from blood or peritoneal cavity. FACS analyses were performed to determine uptake of GeRP by macrophages compared to lymphocytes and to estimate the proportion of CD68 + and CD3 + cells in the white blood cell fraction or in the peritoneal lavage fluid of the GeRP-treated ZDF rats. PECs were prepared as described previously, and the white blood cell fraction was prepared by adding 250 µL of whole blood into a red blood cell lysis buffer for 5 min and centrifuging at 500g for 10 min. The resulting pellets were washed in PBS containing 2% FBS, and cells were then preincubated with Rat BD Fc Block (purified mouse anti-rat CD32, BD Biosciences 550270, San Diego, CA, 1:100) at 4 °C for 10 min and then stained for CD3 (mouse anti-rat CD3, Alexa Fluor 647; MCA772A647, AbD serotec, 1:10) or CD68 (mouse anti-rat CD68, Alexa Fluor 647; MCA341A647, AbD serotec, 1:10) for 30 min at 4 °C. Flow cytometry analysis was performed using a FACSCalibur (BD Biosciences), and quantification of CD3 + and CD68 + cells was achieved using Flowjo software. To assess CD68 + cell-specific and selective knockdown of CB 1 R, we stained PECs with a mouse anti-rat CD3 antibody conjugated to allophycocyanin and a mouse anti-rat CD68 antibody conjugated to phycoerythrin (MCA772A647 and MCA341PE, respectively, AbD Serotec, 1:10). Cells were then maintained in PBS supplemented with 2% FBS and were sorted using a BD FACS Aria. After sorting, the two populations were analyzed separately for Cnr1 and Cnr2 mRNA expression.
Pancreas immunohistology. Pancreas was fixed in 10% neutral buffered formalin (NBF), embedded in paraffin and sectioned (4 µm) onto glass slides. Antibodies used for immunostaining are listed in Supplementary Table 2. Each bound antibody was revealed using the appropriate Elite ABC horseradish peroxidase (HRP)-diaminobenzediene (DAB) system (Vector Labs). To determine whether any colocalization was occurring, we used the same pairs of antibodies listed in Supplementary Table 2 . For detection, secondary antibody coupled to FITC or phycoerythrin was used. Images were viewed with a Fluoview FV10i confocal microscope system (Olympus). Images were then analyzed using ImageJ software, and the presence or absence of colocalization was assessed by calculating the Pearson's coefficient.
TUNEL staining was performed using the TUNEL Apoptosis Detection Kit (GenScript USA). Sections were then counterstained with hematoxylin, Gill's formula (Vector Labs) and analyzed using an Olympus BX41 microscope.
Beta cell mass. Beta cell mass was evaluated by point counting morphometry on insulin antibody-stained sections of pancreas as previously described 69 . Briefly, multiple sections (separated by 80 µm each) from each pancreas were analyzed systematically by using a grid system covering at least 175 fields per rat. Separate images were acquired with a BX41 microscope (Olympus), and relative volumes were calculated for beta cells, non-beta cells and exocrine tissue using ImageJ software. The extent of contaminating tissue (for example, pancreatic ducts, adipose tissue and so on) was recorded in order to correct for the pancreatic weight. Beta cell mass was calculated using the following formula: islet beta cell mass = relative beta cell volume × corrected pancreatic weight.
